课题基金 / 基金详情

Identifying metabolic dependencies in Hurthle cell carcinoma of the thyroid-Res 1

Identifying metabolic dependencies in Hurthle cell carcinoma of the thyroid-Res 1
鉴定甲状腺 Hurthle 细胞癌的代谢依赖性-Res 1
批准号:
10734983
负责人:
David Glenn McFadden
金额:
$52.96万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-07-27 至 2028-06-30

项目摘要

项目成果

David Glenn McFadden的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary: Cancers require metabolic adaptations to support the unbridled proliferation that drives tumor growth. Mutations in the mitochondrial genome (mtDNA) are observed in many cancers, but the role of these mutations in shaping cellular metabolism and tumor growth is incompletely understood. mtDNA mutations that impair components of the electron transport chain (ETC) appear to be selected against in most forms of cancer. Hürthle cell carcinoma of the thyroid (HTC) is clinically aggressive cancer uniquely enriched for loss-of-function mtDNA mutations in components of complex I of the ETC. We propose that HTC represents an ideal disease outlier in which to interrogate the role of mtDNA alterations and ETC function in cancer. In this proposal, we employ unique and highly complementary approaches to characterize the metabolic impact of mtDNA mutations in HTC and other forms of thyroid and kidney cancer. First, we have developed a clinical protocol to monitor central carbon directly in surgical patients using stable isotope tracing (Aim 1). Second, we have identified a synthetic lethal interaction encoded by complex I mutation and identified a promising small molecule therapeutic using patient-derived models (Aim 2). Finally, we have developed novel GEMMs from which to interrogate the role of complex I function in thyroid tumorigenesis (Aim 3). These approaches are highly complementary and synergistic, yet each is independently poised to bridge key knowledge gaps and lead to new insights into metabolic regulation in cancer. The overall goals of this proposal are to characterize the metabolic adaptations necessitated by complex I loss in HTC directly in patients undergoing thyroid surgery, to identify and target metabolic liabilities as a result of metabolic re-wiring downstream of complex I loss, and to determine whether complex I loss acts to promote or alter thyroid tumor formation in mice. These findings will be of immediate and direct relevance to thyroid cancer patients, provide new insights relevant to other tumors harboring mtDNA mutations and have broad implications across cancer types by providing new insights into ETC function in cancer.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
"Comparative gene resequencing in mouse cancer models"
  • 批准号:
    9071038
  • 项目类别:
  • 资助金额:
    $14.32万
  • 财政年份:
    2011
  • 负责人:
    David Glenn McFadden
  • 依托单位:
"Comparative gene resequencing in mouse cancer models"
  • 批准号:
    8519384
  • 项目类别:
  • 资助金额:
    $18.04万
  • 财政年份:
    2011
  • 负责人:
    David Glenn McFadden
  • 依托单位:
"Comparative gene resequencing in mouse cancer models"
  • 批准号:
    8165804
  • 项目类别:
  • 资助金额:
    $17.89万
  • 财政年份:
    2011
  • 负责人:
    David Glenn McFadden
  • 依托单位:
"Comparative gene resequencing in mouse cancer models"
  • 批准号:
    8706084
  • 项目类别:
  • 资助金额:
    $3.71万
  • 财政年份:
    2011
  • 负责人:
    David Glenn McFadden
  • 依托单位:
海外基金